Latest News

A sub-study from the START trial found that higher levels of inflammation averaged over the trial follow-up period were associated with a subsequent higher risk of AIDS, serious non-AIDS complications, or death during 6 years of continuous treatment for HIV. Delaying treatment resulted in higher levels of systemic inflammation during follow-up.
New extended follow-up results from the global ODYSSEY clinical trial confirm that dolutegravir-based regimens are superior to other antiretroviral treatments for children living with HIV.
As part of our 25th anniversary celebrations, we explore our trials that aim to improve quality of life by optimising treatments for people with cancer.
MRC Clinical Trials Unit at UCL researchers and our collaborators will present the latest research from our HIV trials at CROI 2024.
NeoCHG found that whole-body application of chlorhexidine is safe for hospitalised, premature newborn babies, paving the way for larger clinical trials to test how well it prevents deaths.